Needham sets USD 22.00 target for NeoGenomics stock
Published on 10/15/2026 at 21:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst view and reporting date
- Needham lifted its NeoGenomics target to USD 22.00 on October 6, 2026.
- NeoGenomics will report third-quarter 2026 results on October 28, 2026.
- NeoGenomics stock costs EUR 15.30 at Lang & Schwarz on October 15, 2026 at 9:04 p.m. CEST.
- NeoGenomics had a market capitalization of USD 2.2 billion on October 15, 2026.
Needham lifted its price target for NeoGenomics from USD 19.00 to USD 22.00 on October 6, 2026, according to MarketBeat. Against the Nasdaq quote of USD 17.18, the target sits 28.06 percent higher. NeoGenomics stock was trading at EUR 15.30 at Lang & Schwarz on October 15, 2026 at 9:04 p.m. CEST.
Results date sets the next marker
NeoGenomics will report its third-quarter 2026 financial results after the US market close on October 28, 2026. The company will hold its results call at 4:30 p.m. EDT, as stated by Business Wire.
The date gives the analyst target a near-term test. Investors will be able to compare the announced third-quarter figures with the USD 22.00 valuation marker and the latest Nasdaq quotation.
Price position and trading activity
NeoGenomics was last quoted at USD 17.18 on the Nasdaq at 3:07 p.m. EDT on October 15, 2026. Its 52-week range was USD 7.07 to USD 20.15, putting the share 14.74 percent below the high. Trading volume stood at 663,021 shares against an average of 2,375,354 shares.
The stock's year-to-date performance was 47.60 percent on October 6, 2026, according to Yahoo Finance. NeoGenomics describes its business as oncology-focused cancer diagnostics and information services for providers, hospitals and pharmaceutical companies.
Valuation and peer comparison
NeoGenomics had a market capitalization of USD 2.2 billion and a trailing P/E ratio of minus 8.65 on October 15, 2026. The company does not pay a dividend, while the scheduled October 28 results call remains the next dated event.
Comparison with peers
NEO (Nasdaq, USD): plus 1.78 percent, P/E minus 8.65, market capitalization USD 2.2 billion
Thermo Fisher Scientific (NYSE, USD): plus 4.15 percent, P/E 37.70, market capitalization USD 259.2 billion
Quest Diagnostics (NYSE, USD): plus 1.85 percent, P/E 25.24, market capitalization USD 26.2 billion
Euro quote after the Xetra close
At Lang & Schwarz, NeoGenomics was trading at EUR 15.30 on October 15, 2026 at 9:04 p.m. CEST in the after-hours phase. The Nasdaq quotation was USD 17.18 at 3:07 p.m. EDT on the same date.
The further course of trading is shown by the continuously updated real-time quote of NeoGenomics stock.
NeoGenomics market snapshot
- Company: NeoGenomics, Inc.
- ISIN: US64049M2098
- Ticker: NEO
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 9:04 p.m. CEST): EUR 15.30
- Market capitalization: USD 2.2 billion (as of October 15, 2026)
- 52-week range: USD 7.07-20.15 (as of October 15, 2026)
- Sector / Industry: Healthcare / Health Care Providers and Services
- Next earnings date: October 28, 2026
Market context: Market report S&P 500.
